Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$237.83 USD
+1.13 (0.48%)
Updated Jul 19, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Detailed Estimates
EPS Estimates
Earnings Date | *BMO8/1/24 |
---|---|
Current Quarter | -0.71 |
EPS Last Quarter | -0.16 |
Last EPS Surprise | 78.67% |
ABR | 1.78 |
Earnings ESP
|
-33.59% |
---|---|
Current Year | -2.13 |
Next Year | -0.63 |
EPS (TTM) | -2.32 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 452.73M | 461.23M | 1.88B | 2.24B |
# of Estimates | 11 | 11 | 12 | 12 |
High Estimate | 492.00M | 495.50M | 1.94B | 2.53B |
Low Estimate | 430.49M | 443.00M | 1.83B | 1.94B |
Year ago Sales | 318.75M | 750.53M | 1.83B | 1.88B |
Year over Year Growth Est. | 42.03% | -38.55% | 2.81% | 19.18% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.71 | -0.70 | -2.13 | -0.63 |
# of Estimates | 9 | 9 | 9 | 9 |
Most Recent Consensus | -0.88 | -0.74 | -2.46 | -2.21 |
High Estimate | -0.38 | -0.41 | -1.69 | 1.72 |
Low Estimate | -0.95 | -1.02 | -2.60 | -2.21 |
Year ago EPS | -2.21 | 1.15 | -3.52 | -2.13 |
Year over Year Growth Est. | 67.87% | -160.87% | 39.49% | 70.84% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 1 | 2 | 2 | 2 |
Up Last 60 Days | 2 | 1 | 3 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 1 |
Down Last 60 Days | 1 | 1 | 0 | 2 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.71 | -0.70 | -2.13 | -0.63 |
7 Days Ago | -0.71 | -0.70 | -2.13 | -0.63 |
30 Days Ago | -0.75 | -0.74 | -2.31 | -0.83 |
60 Days Ago | -0.74 | -0.73 | -2.39 | -0.62 |
90 Days Ago | -0.72 | -0.76 | -2.75 | -0.72 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.95 | -0.92 | -2.41 | -1.41 |
Zacks Consensus Estimate | -0.71 | -0.70 | -2.13 | -0.63 |
Earnings ESP | -33.59% | -29.89% | -12.91% | -124.87% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.16 | -1.10 | 1.15 | -2.21 | NA |
Estimate | -0.75 | -1.20 | -1.61 | -1.72 | NA |
Difference | 0.59 | 0.10 | 2.76 | -0.49 | 0.74 |
Surprise | 78.67% | 8.33% | 171.43% | -28.49% | 57.49% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more